Form 4: Akari Therapeutics CEO Receives Stock Grant
Insider Transaction (Form 4)
Abizer Gaslightwala, CEO and a Director of Akari Therapeutics Plc, received 6,430 shares of common stock on September 29, 2026.
Summary
- Grant/award: acquired 6,430 American Depositary Shares representing Ordinary Shares at $9.72 ($62,500) on September 29, 2026; holds 14,107 after (Direct).
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as routine: the reported changes are grants, option exercises, tax withholding or similar administrative transactions, which carry limited directional signal.
Insider Transactions
Abizer Gaslightwala — Director, Officer (CEO)
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-09-29 | Grant/award | American Depositary Shares representing Ordinary Shares | 6,430 | $10 | $62.5K | 14,107 |
Key Dates
| Date | Description |
|---|---|
| 2026-09-29 | Grant/award (6,430 shares) |
Keywords
insider transaction, Form 4, AKTX, Akari Therapeutics Plc, neutral, Abizer Gaslightwala
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.